nodes	percent_of_prediction	percent_of_DWPC	metapath
Tiagabine—CYP3A4—prostate cancer	0.263	1	CbGaD
Tiagabine—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.0795	0.207	CbGbCtD
Tiagabine—CYP3A4—Bicalutamide—prostate cancer	0.0418	0.109	CbGbCtD
Tiagabine—CYP3A4—Estramustine—prostate cancer	0.0388	0.101	CbGbCtD
Tiagabine—CYP3A4—Flutamide—prostate cancer	0.0346	0.09	CbGbCtD
Tiagabine—CYP3A4—Abiraterone—prostate cancer	0.0346	0.09	CbGbCtD
Tiagabine—CYP3A4—Cabazitaxel—prostate cancer	0.0256	0.0666	CbGbCtD
Tiagabine—CYP3A4—Estrone—prostate cancer	0.025	0.0651	CbGbCtD
Tiagabine—CYP3A4—Ethinyl Estradiol—prostate cancer	0.0223	0.058	CbGbCtD
Tiagabine—CYP3A4—Conjugated Estrogens—prostate cancer	0.0164	0.0426	CbGbCtD
Tiagabine—CYP3A4—Mitoxantrone—prostate cancer	0.0149	0.0387	CbGbCtD
Tiagabine—CYP3A4—Estradiol—prostate cancer	0.0144	0.0374	CbGbCtD
Tiagabine—CYP3A4—Prednisone—prostate cancer	0.0124	0.0321	CbGbCtD
Tiagabine—CYP3A4—Etoposide—prostate cancer	0.00938	0.0244	CbGbCtD
Tiagabine—CYP3A4—Docetaxel—prostate cancer	0.00858	0.0223	CbGbCtD
Tiagabine—SLC6A1—prostate gland—prostate cancer	0.00765	0.286	CbGeAlD
Tiagabine—SLC6A1—seminal vesicle—prostate cancer	0.00647	0.242	CbGeAlD
Tiagabine—CYP3A4—Doxorubicin—prostate cancer	0.0064	0.0166	CbGbCtD
Tiagabine—SLC6A1—urethra—prostate cancer	0.00512	0.191	CbGeAlD
Tiagabine—SLC6A1—testis—prostate cancer	0.00337	0.126	CbGeAlD
Tiagabine—CYP3A4—urine—prostate cancer	0.00333	0.125	CbGeAlD
Tiagabine—CYP3A4—renal system—prostate cancer	0.000816	0.0305	CbGeAlD
Tiagabine—CYP3A4—Metapathway biotransformation—GSTK1—prostate cancer	0.000224	0.00301	CbGpPWpGaD
Tiagabine—CYP3A4—Tamoxifen metabolism—CYP2A6—prostate cancer	0.000223	0.003	CbGpPWpGaD
Tiagabine—CYP3A4—Tryptophan metabolism—CYP7B1—prostate cancer	0.000221	0.00297	CbGpPWpGaD
Tiagabine—CYP3A4—Constitutive Androstane Receptor Pathway—GSTA2—prostate cancer	0.000218	0.00293	CbGpPWpGaD
Tiagabine—SLC6A1—Transmembrane transport of small molecules—SLC22A1—prostate cancer	0.000216	0.00291	CbGpPWpGaD
Tiagabine—CYP3A4—Constitutive Androstane Receptor Pathway—SULT1A1—prostate cancer	0.000215	0.00289	CbGpPWpGaD
Tiagabine—CYP3A4—Estrogen metabolism—NQO1—prostate cancer	0.000212	0.00285	CbGpPWpGaD
Tiagabine—SLC6A1—Transmembrane transport of small molecules—GNG5—prostate cancer	0.000206	0.00276	CbGpPWpGaD
Tiagabine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCG5—prostate cancer	0.000205	0.00276	CbGpPWpGaD
Tiagabine—CYP3A4—Estrogen metabolism—CYP1B1—prostate cancer	0.000203	0.00274	CbGpPWpGaD
Tiagabine—CYP3A4—Xenobiotics—CYP2E1—prostate cancer	0.000197	0.00265	CbGpPWpGaD
Tiagabine—CYP3A4—Tamoxifen metabolism—CYP2E1—prostate cancer	0.00019	0.00255	CbGpPWpGaD
Tiagabine—CYP3A4—Aflatoxin activation and detoxification—GGT1—prostate cancer	0.000189	0.00254	CbGpPWpGaD
Tiagabine—CYP3A4—Phase 1 - Functionalization of compounds—CYP3A43—prostate cancer	0.000186	0.0025	CbGpPWpGaD
Tiagabine—CYP3A4—Constitutive Androstane Receptor Pathway—SULT2A1—prostate cancer	0.000185	0.00249	CbGpPWpGaD
Tiagabine—CYP3A4—Tamoxifen metabolism—CYP1B1—prostate cancer	0.00018	0.00242	CbGpPWpGaD
Tiagabine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP7B1—prostate cancer	0.000178	0.0024	CbGpPWpGaD
Tiagabine—CYP3A4—Estrogen metabolism—COMT—prostate cancer	0.000178	0.00239	CbGpPWpGaD
Tiagabine—CYP3A4—Farnesoid X Receptor  Pathway—RXRA—prostate cancer	0.000177	0.00238	CbGpPWpGaD
Tiagabine—CYP3A4—Oxidation by Cytochrome P450—CYP7B1—prostate cancer	0.000176	0.00237	CbGpPWpGaD
Tiagabine—SLC6A1—Transmembrane transport of small molecules—PRKACB—prostate cancer	0.000175	0.00236	CbGpPWpGaD
Tiagabine—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—prostate cancer	0.000175	0.00235	CbGpPWpGaD
Tiagabine—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—prostate cancer	0.000169	0.00228	CbGpPWpGaD
Tiagabine—SLC6A1—Transmission across Chemical Synapses—MDM2—prostate cancer	0.000166	0.00223	CbGpPWpGaD
Tiagabine—SLC6A1—Transmembrane transport of small molecules—NCOA2—prostate cancer	0.000165	0.00222	CbGpPWpGaD
Tiagabine—CYP3A4—Constitutive Androstane Receptor Pathway—CYP2C19—prostate cancer	0.000165	0.00222	CbGpPWpGaD
Tiagabine—CYP3A4—Estrogen metabolism—GSTM1—prostate cancer	0.000163	0.00219	CbGpPWpGaD
Tiagabine—CYP3A4—Constitutive Androstane Receptor Pathway—CYP2A6—prostate cancer	0.000159	0.00214	CbGpPWpGaD
Tiagabine—SLC6A1—Transmembrane transport of small molecules—SLC5A5—prostate cancer	0.000158	0.00212	CbGpPWpGaD
Tiagabine—CYP3A4—Estrogen metabolism—CYP1A1—prostate cancer	0.000154	0.00207	CbGpPWpGaD
Tiagabine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP3A5—prostate cancer	0.000153	0.00206	CbGpPWpGaD
Tiagabine—CYP3A4—Oxidation by Cytochrome P450—CYP3A5—prostate cancer	0.000151	0.00203	CbGpPWpGaD
Tiagabine—CYP3A4—Tryptophan metabolism—CYP2C18—prostate cancer	0.000149	0.002	CbGpPWpGaD
Tiagabine—SLC6A1—NRF2 pathway—TGFB1—prostate cancer	0.000149	0.002	CbGpPWpGaD
Tiagabine—CYP3A4—Irinotecan Pathway—APC—prostate cancer	0.000148	0.00199	CbGpPWpGaD
Tiagabine—CYP3A4—Constitutive Androstane Receptor Pathway—NCOA2—prostate cancer	0.000145	0.00195	CbGpPWpGaD
Tiagabine—CYP3A4—Phase 1 - Functionalization of compounds—CYP7B1—prostate cancer	0.000145	0.00194	CbGpPWpGaD
Tiagabine—CYP3A4—Xenobiotics—CYP1A1—prostate cancer	0.000142	0.00191	CbGpPWpGaD
Tiagabine—SLC6A1—Transmembrane transport of small molecules—NCOA1—prostate cancer	0.000139	0.00187	CbGpPWpGaD
Tiagabine—CYP3A4—Tamoxifen metabolism—CYP1A1—prostate cancer	0.000136	0.00183	CbGpPWpGaD
Tiagabine—CYP3A4—Cytochrome P450 - arranged by substrate type—TBXAS1—prostate cancer	0.000135	0.00182	CbGpPWpGaD
Tiagabine—SLC6A1—Transmembrane transport of small molecules—RXRA—prostate cancer	0.000132	0.00178	CbGpPWpGaD
Tiagabine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2E1—prostate cancer	0.000129	0.00174	CbGpPWpGaD
Tiagabine—SLC6A1—Neuronal System—MDM2—prostate cancer	0.000127	0.00171	CbGpPWpGaD
Tiagabine—CYP3A4—Phase 1 - Functionalization of compounds—CYP3A5—prostate cancer	0.000124	0.00167	CbGpPWpGaD
Tiagabine—CYP3A4—Constitutive Androstane Receptor Pathway—NCOA1—prostate cancer	0.000122	0.00165	CbGpPWpGaD
Tiagabine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2C18—prostate cancer	0.00012	0.00162	CbGpPWpGaD
Tiagabine—CYP3A4—Oxidation by Cytochrome P450—CYP2C18—prostate cancer	0.000119	0.0016	CbGpPWpGaD
Tiagabine—CYP3A4—Constitutive Androstane Receptor Pathway—RXRA—prostate cancer	0.000116	0.00157	CbGpPWpGaD
Tiagabine—CYP3A4—Biological oxidations—UGT2B15—prostate cancer	0.000111	0.00149	CbGpPWpGaD
Tiagabine—CYP3A4—Biological oxidations—UGT2B17—prostate cancer	0.000111	0.00149	CbGpPWpGaD
Tiagabine—CYP3A4—Phase 1 - Functionalization of compounds—TBXAS1—prostate cancer	0.00011	0.00147	CbGpPWpGaD
Tiagabine—CYP3A4—Metapathway biotransformation—UGT2B17—prostate cancer	0.000109	0.00147	CbGpPWpGaD
Tiagabine—CYP3A4—Biological oxidations—GSTM3—prostate cancer	0.000104	0.0014	CbGpPWpGaD
Tiagabine—CYP3A4—Biological oxidations—SULT2B1—prostate cancer	0.000104	0.0014	CbGpPWpGaD
Tiagabine—CYP3A4—Metapathway biotransformation—SULT2B1—prostate cancer	0.000103	0.00138	CbGpPWpGaD
Tiagabine—CYP3A4—Metapathway biotransformation—GSTM3—prostate cancer	0.000103	0.00138	CbGpPWpGaD
Tiagabine—CYP3A4—Tryptophan metabolism—CYP2E1—prostate cancer	0.000101	0.00136	CbGpPWpGaD
Tiagabine—SLC6A1—Transmembrane transport of small molecules—PPARA—prostate cancer	0.000101	0.00136	CbGpPWpGaD
Tiagabine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—prostate cancer	0.000101	0.00135	CbGpPWpGaD
Tiagabine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2C19—prostate cancer	9.98e-05	0.00134	CbGpPWpGaD
Tiagabine—CYP3A4—Biological oxidations—CYP3A43—prostate cancer	9.88e-05	0.00133	CbGpPWpGaD
Tiagabine—CYP3A4—Biological oxidations—NAT1—prostate cancer	9.88e-05	0.00133	CbGpPWpGaD
Tiagabine—CYP3A4—Oxidation by Cytochrome P450—CYP2C19—prostate cancer	9.85e-05	0.00133	CbGpPWpGaD
Tiagabine—CYP3A4—Phase 1 - Functionalization of compounds—CYP2C18—prostate cancer	9.77e-05	0.00131	CbGpPWpGaD
Tiagabine—CYP3A4—Metapathway biotransformation—CYP3A43—prostate cancer	9.74e-05	0.00131	CbGpPWpGaD
Tiagabine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A6—prostate cancer	9.63e-05	0.0013	CbGpPWpGaD
Tiagabine—CYP3A4—Tryptophan metabolism—CYP1B1—prostate cancer	9.6e-05	0.00129	CbGpPWpGaD
Tiagabine—CYP3A4—Oxidation by Cytochrome P450—CYP2A6—prostate cancer	9.51e-05	0.00128	CbGpPWpGaD
Tiagabine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP17A1—prostate cancer	9.22e-05	0.00124	CbGpPWpGaD
Tiagabine—CYP3A4—Oxidation by Cytochrome P450—CYP17A1—prostate cancer	9.1e-05	0.00122	CbGpPWpGaD
Tiagabine—CYP3A4—Tryptophan metabolism—CYP19A1—prostate cancer	9.03e-05	0.00121	CbGpPWpGaD
Tiagabine—CYP3A4—Cytochrome P450 - arranged by substrate type—NCOA2—prostate cancer	8.79e-05	0.00118	CbGpPWpGaD
Tiagabine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARA—prostate cancer	8.48e-05	0.00114	CbGpPWpGaD
Tiagabine—CYP3A4—Metapathway biotransformation—EPHX1—prostate cancer	8.28e-05	0.00111	CbGpPWpGaD
Tiagabine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2E1—prostate cancer	8.19e-05	0.0011	CbGpPWpGaD
Tiagabine—CYP3A4—Phase 1 - Functionalization of compounds—CYP2C19—prostate cancer	8.09e-05	0.00109	CbGpPWpGaD
Tiagabine—CYP3A4—Oxidation by Cytochrome P450—CYP2E1—prostate cancer	8.08e-05	0.00109	CbGpPWpGaD
Tiagabine—SLC6A1—Transmembrane transport of small molecules—CREBBP—prostate cancer	8.03e-05	0.00108	CbGpPWpGaD
Tiagabine—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A6—prostate cancer	7.81e-05	0.00105	CbGpPWpGaD
Tiagabine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—prostate cancer	7.76e-05	0.00104	CbGpPWpGaD
Tiagabine—CYP3A4—Biological oxidations—CYP7B1—prostate cancer	7.68e-05	0.00103	CbGpPWpGaD
Tiagabine—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—prostate cancer	7.66e-05	0.00103	CbGpPWpGaD
Tiagabine—CYP3A4—Metapathway biotransformation—CYP7B1—prostate cancer	7.58e-05	0.00102	CbGpPWpGaD
Tiagabine—CYP3A4—Biological oxidations—SULT1E1—prostate cancer	7.49e-05	0.00101	CbGpPWpGaD
Tiagabine—CYP3A4—Phase 1 - Functionalization of compounds—CYP17A1—prostate cancer	7.48e-05	0.00101	CbGpPWpGaD
Tiagabine—CYP3A4—Cytochrome P450 - arranged by substrate type—NCOA1—prostate cancer	7.41e-05	0.000996	CbGpPWpGaD
Tiagabine—CYP3A4—Metapathway biotransformation—SULT1E1—prostate cancer	7.38e-05	0.000993	CbGpPWpGaD
Tiagabine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—prostate cancer	7.3e-05	0.000982	CbGpPWpGaD
Tiagabine—CYP3A4—Tryptophan metabolism—CYP1A1—prostate cancer	7.28e-05	0.000979	CbGpPWpGaD
Tiagabine—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—prostate cancer	7.2e-05	0.000969	CbGpPWpGaD
Tiagabine—CYP3A4—Phase 1 - Functionalization of compounds—NCOA2—prostate cancer	7.13e-05	0.000958	CbGpPWpGaD
Tiagabine—CYP3A4—Cytochrome P450 - arranged by substrate type—RXRA—prostate cancer	7.05e-05	0.000947	CbGpPWpGaD
Tiagabine—CYP3A4—Phase 1 - Functionalization of compounds—CYP2E1—prostate cancer	6.64e-05	0.000893	CbGpPWpGaD
Tiagabine—CYP3A4—Biological oxidations—CYP3A5—prostate cancer	6.59e-05	0.000886	CbGpPWpGaD
Tiagabine—CYP3A4—Metapathway biotransformation—CYP3A5—prostate cancer	6.5e-05	0.000874	CbGpPWpGaD
Tiagabine—CYP3A4—Biological oxidations—GSTA3—prostate cancer	6.37e-05	0.000856	CbGpPWpGaD
Tiagabine—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—prostate cancer	6.29e-05	0.000846	CbGpPWpGaD
Tiagabine—CYP3A4—Metapathway biotransformation—GSTA3—prostate cancer	6.28e-05	0.000844	CbGpPWpGaD
Tiagabine—CYP3A4—Phase 1 - Functionalization of compounds—NCOA1—prostate cancer	6e-05	0.000808	CbGpPWpGaD
Tiagabine—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—prostate cancer	5.92e-05	0.000796	CbGpPWpGaD
Tiagabine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—prostate cancer	5.88e-05	0.000791	CbGpPWpGaD
Tiagabine—CYP3A4—Biological oxidations—GSTA4—prostate cancer	5.82e-05	0.000783	CbGpPWpGaD
Tiagabine—CYP3A4—Biological oxidations—TBXAS1—prostate cancer	5.82e-05	0.000783	CbGpPWpGaD
Tiagabine—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—prostate cancer	5.81e-05	0.000781	CbGpPWpGaD
Tiagabine—CYP3A4—Metapathway biotransformation—GSTA4—prostate cancer	5.74e-05	0.000772	CbGpPWpGaD
Tiagabine—CYP3A4—Phase 1 - Functionalization of compounds—RXRA—prostate cancer	5.71e-05	0.000768	CbGpPWpGaD
Tiagabine—CYP3A4—Biological oxidations—GSTA2—prostate cancer	5.67e-05	0.000763	CbGpPWpGaD
Tiagabine—CYP3A4—Biological oxidations—SULT1A1—prostate cancer	5.6e-05	0.000754	CbGpPWpGaD
Tiagabine—CYP3A4—Metapathway biotransformation—SULT1A1—prostate cancer	5.53e-05	0.000743	CbGpPWpGaD
Tiagabine—CYP3A4—Biological oxidations—GSTA1—prostate cancer	5.47e-05	0.000736	CbGpPWpGaD
Tiagabine—CYP3A4—Biological oxidations—GSTO1—prostate cancer	5.41e-05	0.000728	CbGpPWpGaD
Tiagabine—CYP3A4—Biological oxidations—NAT2—prostate cancer	5.41e-05	0.000728	CbGpPWpGaD
Tiagabine—CYP3A4—Metapathway biotransformation—GSTO1—prostate cancer	5.34e-05	0.000718	CbGpPWpGaD
Tiagabine—CYP3A4—Metapathway biotransformation—NAT2—prostate cancer	5.34e-05	0.000718	CbGpPWpGaD
Tiagabine—CYP3A4—Biological oxidations—CYP2C18—prostate cancer	5.19e-05	0.000698	CbGpPWpGaD
Tiagabine—CYP3A4—Metapathway biotransformation—CYP2C18—prostate cancer	5.12e-05	0.000688	CbGpPWpGaD
Tiagabine—CYP3A4—Biological oxidations—SULT2A1—prostate cancer	4.82e-05	0.000649	CbGpPWpGaD
Tiagabine—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—prostate cancer	4.77e-05	0.000642	CbGpPWpGaD
Tiagabine—CYP3A4—Metapathway biotransformation—SULT2A1—prostate cancer	4.76e-05	0.00064	CbGpPWpGaD
Tiagabine—CYP3A4—Metapathway biotransformation—GPX3—prostate cancer	4.54e-05	0.00061	CbGpPWpGaD
Tiagabine—CYP3A4—Tryptophan metabolism—MDM2—prostate cancer	4.49e-05	0.000604	CbGpPWpGaD
Tiagabine—CYP3A4—Biological oxidations—HPGDS—prostate cancer	4.33e-05	0.000582	CbGpPWpGaD
Tiagabine—CYP3A4—Biological oxidations—CYP2C19—prostate cancer	4.3e-05	0.000578	CbGpPWpGaD
Tiagabine—CYP3A4—Metapathway biotransformation—CYP2C19—prostate cancer	4.24e-05	0.00057	CbGpPWpGaD
Tiagabine—CYP3A4—Biological oxidations—GSTT1—prostate cancer	4.2e-05	0.000564	CbGpPWpGaD
Tiagabine—CYP3A4—Biological oxidations—CYP2A6—prostate cancer	4.15e-05	0.000558	CbGpPWpGaD
Tiagabine—CYP3A4—Metapathway biotransformation—AKR1C3—prostate cancer	3.98e-05	0.000535	CbGpPWpGaD
Tiagabine—CYP3A4—Biological oxidations—CYP17A1—prostate cancer	3.97e-05	0.000534	CbGpPWpGaD
Tiagabine—Anorexia—Docetaxel—prostate cancer	3.97e-05	0.000158	CcSEcCtD
Tiagabine—Malaise—Prednisone—prostate cancer	3.97e-05	0.000158	CcSEcCtD
Tiagabine—Shock—Capecitabine—prostate cancer	3.97e-05	0.000158	CcSEcCtD
Tiagabine—Rhinitis—Epirubicin—prostate cancer	3.97e-05	0.000158	CcSEcCtD
Tiagabine—Body temperature increased—Etoposide—prostate cancer	3.96e-05	0.000158	CcSEcCtD
Tiagabine—Abdominal pain—Etoposide—prostate cancer	3.96e-05	0.000158	CcSEcCtD
Tiagabine—Conjunctivitis—Doxorubicin—prostate cancer	3.96e-05	0.000158	CcSEcCtD
Tiagabine—Urinary tract infection—Doxorubicin—prostate cancer	3.96e-05	0.000158	CcSEcCtD
Tiagabine—Vertigo—Prednisone—prostate cancer	3.96e-05	0.000157	CcSEcCtD
Tiagabine—Haemorrhage—Epirubicin—prostate cancer	3.96e-05	0.000157	CcSEcCtD
Tiagabine—Thrombocytopenia—Capecitabine—prostate cancer	3.95e-05	0.000157	CcSEcCtD
Tiagabine—Syncope—Prednisone—prostate cancer	3.95e-05	0.000157	CcSEcCtD
Tiagabine—Tachycardia—Capecitabine—prostate cancer	3.94e-05	0.000157	CcSEcCtD
Tiagabine—Hypoaesthesia—Epirubicin—prostate cancer	3.94e-05	0.000156	CcSEcCtD
Tiagabine—Pharyngitis—Epirubicin—prostate cancer	3.93e-05	0.000156	CcSEcCtD
Tiagabine—CYP3A4—Metapathway biotransformation—CYP17A1—prostate cancer	3.92e-05	0.000527	CbGpPWpGaD
Tiagabine—Sweating—Doxorubicin—prostate cancer	3.91e-05	0.000155	CcSEcCtD
Tiagabine—Hyperhidrosis—Capecitabine—prostate cancer	3.9e-05	0.000155	CcSEcCtD
Tiagabine—Oedema peripheral—Epirubicin—prostate cancer	3.9e-05	0.000155	CcSEcCtD
Tiagabine—Hypotension—Docetaxel—prostate cancer	3.89e-05	0.000155	CcSEcCtD
Tiagabine—Haematuria—Doxorubicin—prostate cancer	3.89e-05	0.000155	CcSEcCtD
Tiagabine—Loss of consciousness—Prednisone—prostate cancer	3.87e-05	0.000154	CcSEcCtD
Tiagabine—Epistaxis—Doxorubicin—prostate cancer	3.85e-05	0.000153	CcSEcCtD
Tiagabine—Anorexia—Capecitabine—prostate cancer	3.85e-05	0.000153	CcSEcCtD
Tiagabine—Nausea—Estradiol—prostate cancer	3.84e-05	0.000153	CcSEcCtD
Tiagabine—Vomiting—Mitoxantrone—prostate cancer	3.83e-05	0.000152	CcSEcCtD
Tiagabine—Sinusitis—Doxorubicin—prostate cancer	3.83e-05	0.000152	CcSEcCtD
Tiagabine—Visual impairment—Epirubicin—prostate cancer	3.81e-05	0.000152	CcSEcCtD
Tiagabine—Hypertension—Prednisone—prostate cancer	3.8e-05	0.000151	CcSEcCtD
Tiagabine—Rash—Mitoxantrone—prostate cancer	3.8e-05	0.000151	CcSEcCtD
Tiagabine—Dermatitis—Mitoxantrone—prostate cancer	3.8e-05	0.000151	CcSEcCtD
Tiagabine—Musculoskeletal discomfort—Docetaxel—prostate cancer	3.8e-05	0.000151	CcSEcCtD
Tiagabine—CYP3A4—Biological oxidations—NCOA2—prostate cancer	3.79e-05	0.000509	CbGpPWpGaD
Tiagabine—Headache—Mitoxantrone—prostate cancer	3.78e-05	0.00015	CcSEcCtD
Tiagabine—Hypotension—Capecitabine—prostate cancer	3.77e-05	0.00015	CcSEcCtD
Tiagabine—Insomnia—Docetaxel—prostate cancer	3.77e-05	0.00015	CcSEcCtD
Tiagabine—Myalgia—Prednisone—prostate cancer	3.75e-05	0.000149	CcSEcCtD
Tiagabine—Arthralgia—Prednisone—prostate cancer	3.75e-05	0.000149	CcSEcCtD
Tiagabine—Paraesthesia—Docetaxel—prostate cancer	3.74e-05	0.000149	CcSEcCtD
Tiagabine—Anxiety—Prednisone—prostate cancer	3.74e-05	0.000148	CcSEcCtD
Tiagabine—Dyspnoea—Docetaxel—prostate cancer	3.72e-05	0.000148	CcSEcCtD
Tiagabine—Somnolence—Docetaxel—prostate cancer	3.7e-05	0.000147	CcSEcCtD
Tiagabine—Discomfort—Prednisone—prostate cancer	3.7e-05	0.000147	CcSEcCtD
Tiagabine—Hypersensitivity—Etoposide—prostate cancer	3.69e-05	0.000147	CcSEcCtD
Tiagabine—Tinnitus—Epirubicin—prostate cancer	3.69e-05	0.000147	CcSEcCtD
Tiagabine—Haemoglobin—Doxorubicin—prostate cancer	3.68e-05	0.000146	CcSEcCtD
Tiagabine—Musculoskeletal discomfort—Capecitabine—prostate cancer	3.68e-05	0.000146	CcSEcCtD
Tiagabine—Rhinitis—Doxorubicin—prostate cancer	3.67e-05	0.000146	CcSEcCtD
Tiagabine—Dyspepsia—Docetaxel—prostate cancer	3.67e-05	0.000146	CcSEcCtD
Tiagabine—Haemorrhage—Doxorubicin—prostate cancer	3.66e-05	0.000145	CcSEcCtD
Tiagabine—Insomnia—Capecitabine—prostate cancer	3.65e-05	0.000145	CcSEcCtD
Tiagabine—Hypoaesthesia—Doxorubicin—prostate cancer	3.64e-05	0.000145	CcSEcCtD
Tiagabine—Pharyngitis—Doxorubicin—prostate cancer	3.63e-05	0.000144	CcSEcCtD
Tiagabine—Paraesthesia—Capecitabine—prostate cancer	3.62e-05	0.000144	CcSEcCtD
Tiagabine—Decreased appetite—Docetaxel—prostate cancer	3.62e-05	0.000144	CcSEcCtD
Tiagabine—Oedema peripheral—Doxorubicin—prostate cancer	3.61e-05	0.000143	CcSEcCtD
Tiagabine—Asthenia—Etoposide—prostate cancer	3.6e-05	0.000143	CcSEcCtD
Tiagabine—Dyspnoea—Capecitabine—prostate cancer	3.6e-05	0.000143	CcSEcCtD
Tiagabine—Oedema—Prednisone—prostate cancer	3.59e-05	0.000143	CcSEcCtD
Tiagabine—Fatigue—Docetaxel—prostate cancer	3.59e-05	0.000143	CcSEcCtD
Tiagabine—Nausea—Mitoxantrone—prostate cancer	3.58e-05	0.000142	CcSEcCtD
Tiagabine—Infection—Prednisone—prostate cancer	3.57e-05	0.000142	CcSEcCtD
Tiagabine—Constipation—Docetaxel—prostate cancer	3.56e-05	0.000142	CcSEcCtD
Tiagabine—Pain—Docetaxel—prostate cancer	3.56e-05	0.000142	CcSEcCtD
Tiagabine—Dyspepsia—Capecitabine—prostate cancer	3.55e-05	0.000141	CcSEcCtD
Tiagabine—Chills—Epirubicin—prostate cancer	3.55e-05	0.000141	CcSEcCtD
Tiagabine—Pruritus—Etoposide—prostate cancer	3.55e-05	0.000141	CcSEcCtD
Tiagabine—Shock—Prednisone—prostate cancer	3.54e-05	0.000141	CcSEcCtD
Tiagabine—Visual impairment—Doxorubicin—prostate cancer	3.53e-05	0.00014	CcSEcCtD
Tiagabine—CYP3A4—Biological oxidations—CYP2E1—prostate cancer	3.53e-05	0.000474	CbGpPWpGaD
Tiagabine—Tachycardia—Prednisone—prostate cancer	3.51e-05	0.000139	CcSEcCtD
Tiagabine—Decreased appetite—Capecitabine—prostate cancer	3.51e-05	0.000139	CcSEcCtD
Tiagabine—Alopecia—Epirubicin—prostate cancer	3.5e-05	0.000139	CcSEcCtD
Tiagabine—CYP3A4—Metapathway biotransformation—CYP2E1—prostate cancer	3.48e-05	0.000468	CbGpPWpGaD
Tiagabine—Fatigue—Capecitabine—prostate cancer	3.48e-05	0.000138	CcSEcCtD
Tiagabine—Hyperhidrosis—Prednisone—prostate cancer	3.47e-05	0.000138	CcSEcCtD
Tiagabine—Constipation—Capecitabine—prostate cancer	3.45e-05	0.000137	CcSEcCtD
Tiagabine—Pain—Capecitabine—prostate cancer	3.45e-05	0.000137	CcSEcCtD
Tiagabine—Feeling abnormal—Docetaxel—prostate cancer	3.43e-05	0.000136	CcSEcCtD
Tiagabine—Diarrhoea—Etoposide—prostate cancer	3.43e-05	0.000136	CcSEcCtD
Tiagabine—Anorexia—Prednisone—prostate cancer	3.43e-05	0.000136	CcSEcCtD
Tiagabine—Tinnitus—Doxorubicin—prostate cancer	3.41e-05	0.000136	CcSEcCtD
Tiagabine—Gastrointestinal pain—Docetaxel—prostate cancer	3.41e-05	0.000135	CcSEcCtD
Tiagabine—Flatulence—Epirubicin—prostate cancer	3.39e-05	0.000135	CcSEcCtD
Tiagabine—Tension—Epirubicin—prostate cancer	3.38e-05	0.000134	CcSEcCtD
Tiagabine—Dysgeusia—Epirubicin—prostate cancer	3.37e-05	0.000134	CcSEcCtD
Tiagabine—Nervousness—Epirubicin—prostate cancer	3.34e-05	0.000133	CcSEcCtD
Tiagabine—CYP3A4—Biological oxidations—CYP1B1—prostate cancer	3.34e-05	0.00045	CbGpPWpGaD
Tiagabine—Back pain—Epirubicin—prostate cancer	3.33e-05	0.000132	CcSEcCtD
Tiagabine—Feeling abnormal—Capecitabine—prostate cancer	3.32e-05	0.000132	CcSEcCtD
Tiagabine—Dizziness—Etoposide—prostate cancer	3.32e-05	0.000132	CcSEcCtD
Tiagabine—Muscle spasms—Epirubicin—prostate cancer	3.31e-05	0.000132	CcSEcCtD
Tiagabine—Gastrointestinal pain—Capecitabine—prostate cancer	3.3e-05	0.000131	CcSEcCtD
Tiagabine—CYP3A4—Metapathway biotransformation—CYP1B1—prostate cancer	3.3e-05	0.000443	CbGpPWpGaD
Tiagabine—Abdominal pain—Docetaxel—prostate cancer	3.29e-05	0.000131	CcSEcCtD
Tiagabine—Body temperature increased—Docetaxel—prostate cancer	3.29e-05	0.000131	CcSEcCtD
Tiagabine—Chills—Doxorubicin—prostate cancer	3.28e-05	0.000131	CcSEcCtD
Tiagabine—Musculoskeletal discomfort—Prednisone—prostate cancer	3.27e-05	0.00013	CcSEcCtD
Tiagabine—Insomnia—Prednisone—prostate cancer	3.25e-05	0.000129	CcSEcCtD
Tiagabine—CYP3A4—Biological oxidations—GGT1—prostate cancer	3.24e-05	0.000435	CbGpPWpGaD
Tiagabine—Alopecia—Doxorubicin—prostate cancer	3.23e-05	0.000129	CcSEcCtD
Tiagabine—Paraesthesia—Prednisone—prostate cancer	3.23e-05	0.000128	CcSEcCtD
Tiagabine—Urticaria—Capecitabine—prostate cancer	3.21e-05	0.000127	CcSEcCtD
Tiagabine—Ill-defined disorder—Epirubicin—prostate cancer	3.2e-05	0.000127	CcSEcCtD
Tiagabine—CYP3A4—Biological oxidations—NCOA1—prostate cancer	3.19e-05	0.000429	CbGpPWpGaD
Tiagabine—Body temperature increased—Capecitabine—prostate cancer	3.19e-05	0.000127	CcSEcCtD
Tiagabine—Abdominal pain—Capecitabine—prostate cancer	3.19e-05	0.000127	CcSEcCtD
Tiagabine—Vomiting—Etoposide—prostate cancer	3.19e-05	0.000127	CcSEcCtD
Tiagabine—Anaemia—Epirubicin—prostate cancer	3.18e-05	0.000127	CcSEcCtD
Tiagabine—Agitation—Epirubicin—prostate cancer	3.16e-05	0.000126	CcSEcCtD
Tiagabine—Dyspepsia—Prednisone—prostate cancer	3.16e-05	0.000126	CcSEcCtD
Tiagabine—Rash—Etoposide—prostate cancer	3.16e-05	0.000126	CcSEcCtD
Tiagabine—Dermatitis—Etoposide—prostate cancer	3.16e-05	0.000126	CcSEcCtD
Tiagabine—CYP3A4—Biological oxidations—CYP19A1—prostate cancer	3.14e-05	0.000423	CbGpPWpGaD
Tiagabine—Headache—Etoposide—prostate cancer	3.14e-05	0.000125	CcSEcCtD
Tiagabine—Flatulence—Doxorubicin—prostate cancer	3.14e-05	0.000125	CcSEcCtD
Tiagabine—Tension—Doxorubicin—prostate cancer	3.13e-05	0.000124	CcSEcCtD
Tiagabine—Decreased appetite—Prednisone—prostate cancer	3.12e-05	0.000124	CcSEcCtD
Tiagabine—Dysgeusia—Doxorubicin—prostate cancer	3.12e-05	0.000124	CcSEcCtD
Tiagabine—Malaise—Epirubicin—prostate cancer	3.11e-05	0.000123	CcSEcCtD
Tiagabine—CYP3A4—Metapathway biotransformation—CYP19A1—prostate cancer	3.1e-05	0.000417	CbGpPWpGaD
Tiagabine—Fatigue—Prednisone—prostate cancer	3.1e-05	0.000123	CcSEcCtD
Tiagabine—Nervousness—Doxorubicin—prostate cancer	3.09e-05	0.000123	CcSEcCtD
Tiagabine—Vertigo—Epirubicin—prostate cancer	3.09e-05	0.000123	CcSEcCtD
Tiagabine—Syncope—Epirubicin—prostate cancer	3.09e-05	0.000123	CcSEcCtD
Tiagabine—Leukopenia—Epirubicin—prostate cancer	3.08e-05	0.000123	CcSEcCtD
Tiagabine—Back pain—Doxorubicin—prostate cancer	3.08e-05	0.000123	CcSEcCtD
Tiagabine—Constipation—Prednisone—prostate cancer	3.07e-05	0.000122	CcSEcCtD
Tiagabine—Hypersensitivity—Docetaxel—prostate cancer	3.07e-05	0.000122	CcSEcCtD
Tiagabine—Muscle spasms—Doxorubicin—prostate cancer	3.06e-05	0.000122	CcSEcCtD
Tiagabine—Palpitations—Epirubicin—prostate cancer	3.04e-05	0.000121	CcSEcCtD
Tiagabine—CYP3A4—Biological oxidations—RXRA—prostate cancer	3.03e-05	0.000408	CbGpPWpGaD
Tiagabine—Loss of consciousness—Epirubicin—prostate cancer	3.03e-05	0.00012	CcSEcCtD
Tiagabine—Cough—Epirubicin—prostate cancer	3.01e-05	0.000119	CcSEcCtD
Tiagabine—Asthenia—Docetaxel—prostate cancer	2.99e-05	0.000119	CcSEcCtD
Tiagabine—Nausea—Etoposide—prostate cancer	2.98e-05	0.000118	CcSEcCtD
Tiagabine—Hypertension—Epirubicin—prostate cancer	2.97e-05	0.000118	CcSEcCtD
Tiagabine—Hypersensitivity—Capecitabine—prostate cancer	2.97e-05	0.000118	CcSEcCtD
Tiagabine—Feeling abnormal—Prednisone—prostate cancer	2.96e-05	0.000118	CcSEcCtD
Tiagabine—Ill-defined disorder—Doxorubicin—prostate cancer	2.96e-05	0.000118	CcSEcCtD
Tiagabine—Pruritus—Docetaxel—prostate cancer	2.95e-05	0.000117	CcSEcCtD
Tiagabine—Anaemia—Doxorubicin—prostate cancer	2.95e-05	0.000117	CcSEcCtD
Tiagabine—Gastrointestinal pain—Prednisone—prostate cancer	2.94e-05	0.000117	CcSEcCtD
Tiagabine—Chest pain—Epirubicin—prostate cancer	2.93e-05	0.000117	CcSEcCtD
Tiagabine—Arthralgia—Epirubicin—prostate cancer	2.93e-05	0.000117	CcSEcCtD
Tiagabine—Myalgia—Epirubicin—prostate cancer	2.93e-05	0.000117	CcSEcCtD
Tiagabine—Agitation—Doxorubicin—prostate cancer	2.93e-05	0.000116	CcSEcCtD
Tiagabine—CYP3A4—Biological oxidations—COMT—prostate cancer	2.92e-05	0.000393	CbGpPWpGaD
Tiagabine—Anxiety—Epirubicin—prostate cancer	2.92e-05	0.000116	CcSEcCtD
Tiagabine—CYP3A4—Biological oxidations—GSTP1—prostate cancer	2.91e-05	0.000391	CbGpPWpGaD
Tiagabine—Discomfort—Epirubicin—prostate cancer	2.9e-05	0.000115	CcSEcCtD
Tiagabine—Asthenia—Capecitabine—prostate cancer	2.89e-05	0.000115	CcSEcCtD
Tiagabine—CYP3A4—Metapathway biotransformation—COMT—prostate cancer	2.88e-05	0.000388	CbGpPWpGaD
Tiagabine—Malaise—Doxorubicin—prostate cancer	2.87e-05	0.000114	CcSEcCtD
Tiagabine—CYP3A4—Metapathway biotransformation—GSTP1—prostate cancer	2.87e-05	0.000386	CbGpPWpGaD
Tiagabine—Dry mouth—Epirubicin—prostate cancer	2.87e-05	0.000114	CcSEcCtD
Tiagabine—Vertigo—Doxorubicin—prostate cancer	2.86e-05	0.000114	CcSEcCtD
Tiagabine—Syncope—Doxorubicin—prostate cancer	2.86e-05	0.000114	CcSEcCtD
Tiagabine—Urticaria—Prednisone—prostate cancer	2.85e-05	0.000113	CcSEcCtD
Tiagabine—Pruritus—Capecitabine—prostate cancer	2.85e-05	0.000113	CcSEcCtD
Tiagabine—Leukopenia—Doxorubicin—prostate cancer	2.85e-05	0.000113	CcSEcCtD
Tiagabine—Diarrhoea—Docetaxel—prostate cancer	2.85e-05	0.000113	CcSEcCtD
Tiagabine—Abdominal pain—Prednisone—prostate cancer	2.84e-05	0.000113	CcSEcCtD
Tiagabine—Body temperature increased—Prednisone—prostate cancer	2.84e-05	0.000113	CcSEcCtD
Tiagabine—Confusional state—Epirubicin—prostate cancer	2.83e-05	0.000113	CcSEcCtD
Tiagabine—Palpitations—Doxorubicin—prostate cancer	2.82e-05	0.000112	CcSEcCtD
Tiagabine—Oedema—Epirubicin—prostate cancer	2.81e-05	0.000112	CcSEcCtD
Tiagabine—Loss of consciousness—Doxorubicin—prostate cancer	2.8e-05	0.000111	CcSEcCtD
Tiagabine—Infection—Epirubicin—prostate cancer	2.79e-05	0.000111	CcSEcCtD
Tiagabine—Cough—Doxorubicin—prostate cancer	2.78e-05	0.000111	CcSEcCtD
Tiagabine—Shock—Epirubicin—prostate cancer	2.77e-05	0.00011	CcSEcCtD
Tiagabine—Diarrhoea—Capecitabine—prostate cancer	2.76e-05	0.00011	CcSEcCtD
Tiagabine—Dizziness—Docetaxel—prostate cancer	2.76e-05	0.00011	CcSEcCtD
Tiagabine—Thrombocytopenia—Epirubicin—prostate cancer	2.75e-05	0.000109	CcSEcCtD
Tiagabine—Hypertension—Doxorubicin—prostate cancer	2.75e-05	0.000109	CcSEcCtD
Tiagabine—Tachycardia—Epirubicin—prostate cancer	2.74e-05	0.000109	CcSEcCtD
Tiagabine—Hyperhidrosis—Epirubicin—prostate cancer	2.72e-05	0.000108	CcSEcCtD
Tiagabine—Myalgia—Doxorubicin—prostate cancer	2.71e-05	0.000108	CcSEcCtD
Tiagabine—Chest pain—Doxorubicin—prostate cancer	2.71e-05	0.000108	CcSEcCtD
Tiagabine—Arthralgia—Doxorubicin—prostate cancer	2.71e-05	0.000108	CcSEcCtD
Tiagabine—Anxiety—Doxorubicin—prostate cancer	2.7e-05	0.000107	CcSEcCtD
Tiagabine—Discomfort—Doxorubicin—prostate cancer	2.68e-05	0.000107	CcSEcCtD
Tiagabine—Anorexia—Epirubicin—prostate cancer	2.68e-05	0.000106	CcSEcCtD
Tiagabine—CYP3A4—Biological oxidations—GSTM1—prostate cancer	2.67e-05	0.000359	CbGpPWpGaD
Tiagabine—Dizziness—Capecitabine—prostate cancer	2.67e-05	0.000106	CcSEcCtD
Tiagabine—Dry mouth—Doxorubicin—prostate cancer	2.65e-05	0.000105	CcSEcCtD
Tiagabine—Vomiting—Docetaxel—prostate cancer	2.65e-05	0.000105	CcSEcCtD
Tiagabine—Hypersensitivity—Prednisone—prostate cancer	2.65e-05	0.000105	CcSEcCtD
Tiagabine—CYP3A4—Metapathway biotransformation—GSTM1—prostate cancer	2.64e-05	0.000355	CbGpPWpGaD
Tiagabine—Rash—Docetaxel—prostate cancer	2.63e-05	0.000104	CcSEcCtD
Tiagabine—Hypotension—Epirubicin—prostate cancer	2.63e-05	0.000104	CcSEcCtD
Tiagabine—Dermatitis—Docetaxel—prostate cancer	2.62e-05	0.000104	CcSEcCtD
Tiagabine—Confusional state—Doxorubicin—prostate cancer	2.62e-05	0.000104	CcSEcCtD
Tiagabine—Headache—Docetaxel—prostate cancer	2.61e-05	0.000104	CcSEcCtD
Tiagabine—Oedema—Doxorubicin—prostate cancer	2.6e-05	0.000103	CcSEcCtD
Tiagabine—Infection—Doxorubicin—prostate cancer	2.58e-05	0.000103	CcSEcCtD
Tiagabine—Asthenia—Prednisone—prostate cancer	2.58e-05	0.000102	CcSEcCtD
Tiagabine—Vomiting—Capecitabine—prostate cancer	2.57e-05	0.000102	CcSEcCtD
Tiagabine—Musculoskeletal discomfort—Epirubicin—prostate cancer	2.56e-05	0.000102	CcSEcCtD
Tiagabine—Shock—Doxorubicin—prostate cancer	2.56e-05	0.000102	CcSEcCtD
Tiagabine—Thrombocytopenia—Doxorubicin—prostate cancer	2.55e-05	0.000101	CcSEcCtD
Tiagabine—Rash—Capecitabine—prostate cancer	2.54e-05	0.000101	CcSEcCtD
Tiagabine—Pruritus—Prednisone—prostate cancer	2.54e-05	0.000101	CcSEcCtD
Tiagabine—Insomnia—Epirubicin—prostate cancer	2.54e-05	0.000101	CcSEcCtD
Tiagabine—Dermatitis—Capecitabine—prostate cancer	2.54e-05	0.000101	CcSEcCtD
Tiagabine—Tachycardia—Doxorubicin—prostate cancer	2.54e-05	0.000101	CcSEcCtD
Tiagabine—CYP3A4—Biological oxidations—CYP1A1—prostate cancer	2.53e-05	0.000341	CbGpPWpGaD
Tiagabine—Headache—Capecitabine—prostate cancer	2.53e-05	0.0001	CcSEcCtD
Tiagabine—Paraesthesia—Epirubicin—prostate cancer	2.52e-05	0.0001	CcSEcCtD
Tiagabine—Hyperhidrosis—Doxorubicin—prostate cancer	2.51e-05	9.99e-05	CcSEcCtD
Tiagabine—Dyspnoea—Epirubicin—prostate cancer	2.51e-05	9.96e-05	CcSEcCtD
Tiagabine—CYP3A4—Metabolism—HAO1—prostate cancer	2.5e-05	0.000336	CbGpPWpGaD
Tiagabine—CYP3A4—Metapathway biotransformation—CYP1A1—prostate cancer	2.5e-05	0.000336	CbGpPWpGaD
Tiagabine—Somnolence—Epirubicin—prostate cancer	2.5e-05	9.93e-05	CcSEcCtD
Tiagabine—Anorexia—Doxorubicin—prostate cancer	2.48e-05	9.85e-05	CcSEcCtD
Tiagabine—Nausea—Docetaxel—prostate cancer	2.48e-05	9.84e-05	CcSEcCtD
Tiagabine—Dyspepsia—Epirubicin—prostate cancer	2.47e-05	9.83e-05	CcSEcCtD
Tiagabine—Diarrhoea—Prednisone—prostate cancer	2.46e-05	9.77e-05	CcSEcCtD
Tiagabine—Decreased appetite—Epirubicin—prostate cancer	2.44e-05	9.71e-05	CcSEcCtD
Tiagabine—Hypotension—Doxorubicin—prostate cancer	2.43e-05	9.66e-05	CcSEcCtD
Tiagabine—Fatigue—Epirubicin—prostate cancer	2.42e-05	9.63e-05	CcSEcCtD
Tiagabine—Constipation—Epirubicin—prostate cancer	2.4e-05	9.55e-05	CcSEcCtD
Tiagabine—Pain—Epirubicin—prostate cancer	2.4e-05	9.55e-05	CcSEcCtD
Tiagabine—Nausea—Capecitabine—prostate cancer	2.4e-05	9.52e-05	CcSEcCtD
Tiagabine—Dizziness—Prednisone—prostate cancer	2.38e-05	9.45e-05	CcSEcCtD
Tiagabine—Musculoskeletal discomfort—Doxorubicin—prostate cancer	2.37e-05	9.42e-05	CcSEcCtD
Tiagabine—Insomnia—Doxorubicin—prostate cancer	2.35e-05	9.35e-05	CcSEcCtD
Tiagabine—Paraesthesia—Doxorubicin—prostate cancer	2.34e-05	9.28e-05	CcSEcCtD
Tiagabine—Dyspnoea—Doxorubicin—prostate cancer	2.32e-05	9.22e-05	CcSEcCtD
Tiagabine—Feeling abnormal—Epirubicin—prostate cancer	2.32e-05	9.21e-05	CcSEcCtD
Tiagabine—Somnolence—Doxorubicin—prostate cancer	2.31e-05	9.19e-05	CcSEcCtD
Tiagabine—Gastrointestinal pain—Epirubicin—prostate cancer	2.3e-05	9.13e-05	CcSEcCtD
Tiagabine—Dyspepsia—Doxorubicin—prostate cancer	2.29e-05	9.1e-05	CcSEcCtD
Tiagabine—Vomiting—Prednisone—prostate cancer	2.28e-05	9.08e-05	CcSEcCtD
Tiagabine—Rash—Prednisone—prostate cancer	2.27e-05	9.01e-05	CcSEcCtD
Tiagabine—Dermatitis—Prednisone—prostate cancer	2.26e-05	9e-05	CcSEcCtD
Tiagabine—Decreased appetite—Doxorubicin—prostate cancer	2.26e-05	8.99e-05	CcSEcCtD
Tiagabine—Headache—Prednisone—prostate cancer	2.25e-05	8.95e-05	CcSEcCtD
Tiagabine—Fatigue—Doxorubicin—prostate cancer	2.24e-05	8.91e-05	CcSEcCtD
Tiagabine—Urticaria—Epirubicin—prostate cancer	2.23e-05	8.87e-05	CcSEcCtD
Tiagabine—Constipation—Doxorubicin—prostate cancer	2.22e-05	8.84e-05	CcSEcCtD
Tiagabine—Pain—Doxorubicin—prostate cancer	2.22e-05	8.84e-05	CcSEcCtD
Tiagabine—Abdominal pain—Epirubicin—prostate cancer	2.22e-05	8.83e-05	CcSEcCtD
Tiagabine—Body temperature increased—Epirubicin—prostate cancer	2.22e-05	8.83e-05	CcSEcCtD
Tiagabine—Feeling abnormal—Doxorubicin—prostate cancer	2.14e-05	8.52e-05	CcSEcCtD
Tiagabine—Nausea—Prednisone—prostate cancer	2.13e-05	8.48e-05	CcSEcCtD
Tiagabine—Gastrointestinal pain—Doxorubicin—prostate cancer	2.13e-05	8.45e-05	CcSEcCtD
Tiagabine—Hypersensitivity—Epirubicin—prostate cancer	2.07e-05	8.23e-05	CcSEcCtD
Tiagabine—Urticaria—Doxorubicin—prostate cancer	2.07e-05	8.21e-05	CcSEcCtD
Tiagabine—Abdominal pain—Doxorubicin—prostate cancer	2.06e-05	8.17e-05	CcSEcCtD
Tiagabine—Body temperature increased—Doxorubicin—prostate cancer	2.06e-05	8.17e-05	CcSEcCtD
Tiagabine—CYP3A4—Metabolism—ADI1—prostate cancer	2.04e-05	0.000274	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—CBR1—prostate cancer	2.04e-05	0.000274	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—PSAT1—prostate cancer	2.04e-05	0.000274	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—TST—prostate cancer	2.04e-05	0.000274	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—GRHL1—prostate cancer	2.04e-05	0.000274	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—CSAD—prostate cancer	2.04e-05	0.000274	CbGpPWpGaD
Tiagabine—Asthenia—Epirubicin—prostate cancer	2.02e-05	8.02e-05	CcSEcCtD
Tiagabine—Pruritus—Epirubicin—prostate cancer	1.99e-05	7.9e-05	CcSEcCtD
Tiagabine—Diarrhoea—Epirubicin—prostate cancer	1.92e-05	7.64e-05	CcSEcCtD
Tiagabine—Hypersensitivity—Doxorubicin—prostate cancer	1.92e-05	7.62e-05	CcSEcCtD
Tiagabine—CYP3A4—Metabolism—UGT2B17—prostate cancer	1.9e-05	0.000255	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—UGT2B15—prostate cancer	1.9e-05	0.000255	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—CKMT2—prostate cancer	1.9e-05	0.000255	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—GRHPR—prostate cancer	1.9e-05	0.000255	CbGpPWpGaD
Tiagabine—Asthenia—Doxorubicin—prostate cancer	1.87e-05	7.42e-05	CcSEcCtD
Tiagabine—Dizziness—Epirubicin—prostate cancer	1.86e-05	7.39e-05	CcSEcCtD
Tiagabine—Pruritus—Doxorubicin—prostate cancer	1.84e-05	7.31e-05	CcSEcCtD
Tiagabine—Vomiting—Epirubicin—prostate cancer	1.79e-05	7.1e-05	CcSEcCtD
Tiagabine—CYP3A4—Metabolism—GSTM3—prostate cancer	1.78e-05	0.00024	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—SULT2B1—prostate cancer	1.78e-05	0.00024	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—NAGLU—prostate cancer	1.78e-05	0.00024	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—AOX1—prostate cancer	1.78e-05	0.00024	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—MBTPS1—prostate cancer	1.78e-05	0.00024	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—PGAM2—prostate cancer	1.78e-05	0.00024	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—RFK—prostate cancer	1.78e-05	0.00024	CbGpPWpGaD
Tiagabine—Diarrhoea—Doxorubicin—prostate cancer	1.78e-05	7.07e-05	CcSEcCtD
Tiagabine—Rash—Epirubicin—prostate cancer	1.77e-05	7.04e-05	CcSEcCtD
Tiagabine—Dermatitis—Epirubicin—prostate cancer	1.77e-05	7.04e-05	CcSEcCtD
Tiagabine—Headache—Epirubicin—prostate cancer	1.76e-05	7e-05	CcSEcCtD
Tiagabine—Dizziness—Doxorubicin—prostate cancer	1.72e-05	6.84e-05	CcSEcCtD
Tiagabine—CYP3A4—Metabolism—CYP3A43—prostate cancer	1.69e-05	0.000227	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—AMACR—prostate cancer	1.69e-05	0.000227	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—DEGS1—prostate cancer	1.69e-05	0.000227	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—NAT1—prostate cancer	1.69e-05	0.000227	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—SRD5A2—prostate cancer	1.69e-05	0.000227	CbGpPWpGaD
Tiagabine—Nausea—Epirubicin—prostate cancer	1.67e-05	6.64e-05	CcSEcCtD
Tiagabine—Vomiting—Doxorubicin—prostate cancer	1.65e-05	6.57e-05	CcSEcCtD
Tiagabine—Rash—Doxorubicin—prostate cancer	1.64e-05	6.52e-05	CcSEcCtD
Tiagabine—Dermatitis—Doxorubicin—prostate cancer	1.64e-05	6.51e-05	CcSEcCtD
Tiagabine—Headache—Doxorubicin—prostate cancer	1.63e-05	6.48e-05	CcSEcCtD
Tiagabine—CYP3A4—Metabolism—HSD17B1—prostate cancer	1.61e-05	0.000217	CbGpPWpGaD
Tiagabine—Nausea—Doxorubicin—prostate cancer	1.54e-05	6.14e-05	CcSEcCtD
Tiagabine—CYP3A4—Metabolism—B4GALT4—prostate cancer	1.44e-05	0.000193	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—HPGD—prostate cancer	1.44e-05	0.000193	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—TNFRSF21—prostate cancer	1.35e-05	0.000182	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—CYP7B1—prostate cancer	1.31e-05	0.000177	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—MTAP—prostate cancer	1.31e-05	0.000177	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—SRD5A1—prostate cancer	1.28e-05	0.000172	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—SULT1E1—prostate cancer	1.28e-05	0.000172	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—ACSL4—prostate cancer	1.22e-05	0.000164	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—HSD17B3—prostate cancer	1.22e-05	0.000164	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—UMPS—prostate cancer	1.17e-05	0.000157	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—PHGDH—prostate cancer	1.17e-05	0.000157	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—ARG2—prostate cancer	1.17e-05	0.000157	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—LDHB—prostate cancer	1.15e-05	0.000154	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—CYP3A5—prostate cancer	1.13e-05	0.000152	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—UCP3—prostate cancer	1.09e-05	0.000146	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—TCN2—prostate cancer	1.09e-05	0.000146	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—PDHA1—prostate cancer	1.09e-05	0.000146	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—GSTA3—prostate cancer	1.09e-05	0.000146	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—HSD3B1—prostate cancer	1.04e-05	0.00014	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—SLC22A3—prostate cancer	1.04e-05	0.00014	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—TBXAS1—prostate cancer	9.96e-06	0.000134	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—GSTA4—prostate cancer	9.96e-06	0.000134	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—GSTA2—prostate cancer	9.7e-06	0.00013	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—ABCG5—prostate cancer	9.58e-06	0.000129	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—SULT1A1—prostate cancer	9.58e-06	0.000129	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—GSTA1—prostate cancer	9.36e-06	0.000126	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—NAT2—prostate cancer	9.26e-06	0.000124	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—GSTO1—prostate cancer	9.26e-06	0.000124	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—HSD3B2—prostate cancer	9.26e-06	0.000124	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—LRP2—prostate cancer	8.87e-06	0.000119	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—PLCB2—prostate cancer	8.87e-06	0.000119	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—CYP2C18—prostate cancer	8.87e-06	0.000119	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—P4HB—prostate cancer	8.7e-06	0.000117	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—SLC22A1—prostate cancer	8.47e-06	0.000114	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—SULT2A1—prostate cancer	8.25e-06	0.000111	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—MED12—prostate cancer	8.12e-06	0.000109	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—GNG5—prostate cancer	8.05e-06	0.000108	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—NCOA3—prostate cancer	7.76e-06	0.000104	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—HPGDS—prostate cancer	7.4e-06	9.95e-05	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—CYP2C19—prostate cancer	7.35e-06	9.89e-05	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—GSTT1—prostate cancer	7.18e-06	9.65e-05	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—ACHE—prostate cancer	7.18e-06	9.65e-05	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—CYP2A6—prostate cancer	7.09e-06	9.54e-05	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—AKR1C3—prostate cancer	6.9e-06	9.28e-05	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—PRKACB—prostate cancer	6.86e-06	9.23e-05	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—CYP17A1—prostate cancer	6.79e-06	9.14e-05	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—NCOA2—prostate cancer	6.47e-06	8.71e-05	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—SLC5A5—prostate cancer	6.18e-06	8.3e-05	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—CYP2E1—prostate cancer	6.03e-06	8.11e-05	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—NQO1—prostate cancer	5.96e-06	8.02e-05	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—TH—prostate cancer	5.88e-06	7.9e-05	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—CYP1B1—prostate cancer	5.72e-06	7.69e-05	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—GGT1—prostate cancer	5.54e-06	7.45e-05	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—NCOA1—prostate cancer	5.45e-06	7.34e-05	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—CYP19A1—prostate cancer	5.38e-06	7.23e-05	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—RXRA—prostate cancer	5.19e-06	6.98e-05	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—COMT—prostate cancer	5e-06	6.72e-05	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—GSTP1—prostate cancer	4.97e-06	6.69e-05	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—ITPR1—prostate cancer	4.89e-06	6.58e-05	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—TYMS—prostate cancer	4.62e-06	6.22e-05	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—GSTM1—prostate cancer	4.57e-06	6.15e-05	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—LPL—prostate cancer	4.49e-06	6.03e-05	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—CYP1A1—prostate cancer	4.33e-06	5.83e-05	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—ERCC2—prostate cancer	4.3e-06	5.78e-05	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—MTHFR—prostate cancer	4.04e-06	5.43e-05	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—PPARA—prostate cancer	3.96e-06	5.33e-05	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—CAV1—prostate cancer	3.73e-06	5.01e-05	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—PIK3CG—prostate cancer	3.39e-06	4.56e-05	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—INS—prostate cancer	3.21e-06	4.32e-05	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—CREBBP—prostate cancer	3.15e-06	4.23e-05	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—PIK3CD—prostate cancer	2.98e-06	4.01e-05	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—NOS3—prostate cancer	2.82e-06	3.79e-05	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—PIK3CB—prostate cancer	2.6e-06	3.5e-05	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—PTGS2—prostate cancer	2.58e-06	3.47e-05	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—PTEN—prostate cancer	2.25e-06	3.02e-05	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—EP300—prostate cancer	2.14e-06	2.88e-05	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—PIK3CA—prostate cancer	1.59e-06	2.13e-05	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—AKT1—prostate cancer	1.3e-06	1.74e-05	CbGpPWpGaD
